Skip to main content
OpenTrials
Completed

NCT Number: NCT06165848

Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients

Adequate and effective pain management and prevention of depression are essential in burn patients. This study aims to investigate the effects of ketamine sedation in burn patients in terms of mood disorders, depression, anxiety, and suicidal tendency during intensive care follow-up in the postoperative period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ankara Bilkent Şehir Hastanesi

Ankara, 06800, Turkey (Türkiye)

About this study

Aim: Adequate and effective pain management and prevention of depression are essential in burn patients. This study aims to investigate the effects of ketamine sedation in burn patients in terms of mood disorders, depression, anxiety, and suicidal tendency during intensive care follow-up in the postoperative period.

Methods: The study was conducted with 67 patients between 18 and 65 years of age, who were ASA I-II class, had basic communication skills, no previous diagnosis of psychiatric illness, and no history of neuropsychiatric or cognitive disease or related treatment. After preoxygenation, anesthesia induction was performed with 2 mg/kg IV propofol and 1 mcg/kg IV fentanyl in the general anesthesia group. Anesthesia was continued with a mixture of 0.3-0.5 mcg/kg/min remifentanil, 2% sevoflurane, 50% air, 50% oxygen. In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction; anesthesia was maintained by adding 30-50 mg IV propofol if necessary. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by the psychiatrist.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Who were ASA I-II class,
  • Had basic communication skills,
  • No previous diagnosis of psychiatric illness,
  • No history of neuropsychiatric or cognitive disease or related treatment.

Exclusion criteria

  • With a previous diagnosis of psychiatric illness,
  • Neuropsychiatric or cognitive illness,
  • Or a history of related treatment.

Treatment and study plan

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS),

    Time frame: 72 hours

    In order to determine whether there is negative mood and depression; Montgomery-Asberg Depression Rating Scale (MADRS) was administered by the psychiatrist .

  2. Hamilton Anxiety Rating Scale (HAM-A)

    Time frame: 72 hours

    For anxiety; Hamilton Anxiety Rating Scale (HAM-A) was administered by the psychiatrist .

  3. Beck Suicidal Ideation Scale (BSSI)

    Time frame: 72 hours

    To determine whether there is suicidal ideation; Beck Suicidal Ideation Scale (BSSI) was administered by the psychiatrist .

Sponsors and collaborators

Lead sponsor

T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Dec 12, 2023
Registry last updated
Dec 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.